Sarepta Therapeutics presented the first clinical results from its Phase 1/2 siRNA programs SRP‑1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP‑1003 for myotonic dystrophy type 1 (DM1) during a webcast at 8:30 a.m. Eastern Time on March 25 2026.
The data showed dose‑dependent muscle exposure, early biomarker effects, and favorable tolerability. Most adverse events were mild to moderate and not dose‑dependent, indicating a promising safety profile for the company’s αvβ6 integrin‑targeted siRNA platform.
This milestone represents the first proof‑of‑concept data for Sarepta’s siRNA pipeline, a potential new source of revenue that could broaden the company’s reach beyond its Duchenne muscular dystrophy franchise.
Sarepta acquired the SRP‑1001 and SRP‑1003 programs from Arrowhead Pharmaceuticals in 2024 for a $500 million upfront payment and additional milestone payments. The advancement of SRP‑1003 triggered a $200 million milestone payment to Arrowhead, underscoring the financial impact of the pipeline’s progress.
In 2025, Sarepta reported $2.2 billion in revenue, a 16% year‑over‑year increase, but a GAAP net loss of $713 million. For 2026, the company guided net product revenue to $1.2–$1.4 billion. The siRNA programs are viewed as a future revenue stream that could offset headwinds in the core Duchenne business.
Management highlighted the significance of the results: Louise Rodino‑Klapac noted that the early data showed high levels of siRNA delivery to muscle with no saturation of uptake or dose‑limiting safety signals; Doug Ingram emphasized dose‑dependent increases in plasma and muscle concentration without saturation; and James Richardson remarked that SRP‑1001’s suppression of the target gene was potentially unprecedented and that SRP‑1003 achieved a 50% placebo‑adjusted reduction in DMPK, exceeding preclinical predictions.
The data also provides a critical alternative growth path amid challenges faced by Sarepta’s Elevidys gene therapy, which has experienced safety setbacks and a narrowed indication. The siRNA platform’s validation offers a new avenue to address unmet needs in rare neuromuscular diseases.
Overall, the presentation of these early clinical results marks a pivotal step in de‑risking Sarepta’s siRNA pipeline and signals a potential diversification of its therapeutic portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.